ANGPTL3
Angiopoietin-related protein 3
As of the edition of 20 October 2026, ANGPTL3 (angiopoietin-related protein 3, UniProt Q9Y5C1) has 3 drugs tested at it and 4 companies on the list, 0 on route A and 2 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q9Y5C1
- How well studied
- Drug target: an approved drug acts on it
- Where it sits in the cell
- In more than one place
- Solved structures
- 1
- Disease areas
- Nutrition and metabolism; Inherited and neonatal; Digestive system; Hormones; Pregnancy and women's health; Urinary and reproductive
- Registered trials of its drugs
- 23
Drugs at this target
| Status | Count |
|---|---|
| Marketed | 1 |
| Active | 2 |
| Total | 3 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Evinacumab | Marketed | Phase 3 | Ends 2033 |
| SHR-1918 | Active | Phase 3 | none listed |
| EDP167 | Active | Phase 2 | none listed |
3 of 3 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route B | 2 |
| Engaged | 2 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Regeneron | Route B |
| Ultragenyx Pharmaceutical | Route B |
The other 2 companies at ANGPTL3
In the product4 companies in all; 2 are not named here, and no score is.
See the 4 companies at ANGPTL3, ranked, with the facts behind eachRequest access. Nothing is shown until you do.